Shots: Medtronic launches a new insulin infusion set that can be worn for up to 7days. The infusion set is compatible with all MiniMed 600 and 700 series insulin pumps The extended infusion set utilizes advanced materials that help in reducing insulin preservative loss and maintains its flow & stability. The new tubing connector improves […]Read More
Shots: The approval is based on efficacy results from P-III studies involve assessing Zegalogue vs PBO in children aged 6-17yrs. and in adults with T1D The study met its 1EPs showed an increase in blood glucose of ≥20 mg/dL within 45 minutes, the median time to blood glucose recovery (10min vs 30-45min), following injection of […]Read More
Shots: Genentech reports the new 2yrs. data from part 2 of SUNFISH study assessing Evrysdi vs PBO in people aged 2-25 years with Type 2 or Type 3 SMA Results: improvement in maintained motor function b/w 12-24mos. as measured by MFM-32; change from baseline in SMAIS score; stabilized motor function after 12mos. as per MFM-32, […]Read More
Shots: The Health Canada has granted a NOC which is based on clinical evidence for Remsima/CT-P13 SC vs CT-P13 IV up to 1year in patients with RA. The results demonstrated that switching patients from Remsima IV to its SC formulation @30wks. is comparable to maintaining Remsima SC up to 54wks. The therapy has shown similar […]Read More
Shots: The 4 pivotal HAVEN studies (HAVEN-1, 2, 3, 4) included pooled data from 401 people with hemophilia A with/ out factor VIII inhibitors, with a median duration efficacy period of 120.4wks. Hemlibra maintained low treated bleed rates with ABR remaining low throughout the evaluation period at 1.4. The proportion of participants who experienced 0 […]Read More
Shots: Five-year data from P-III MURANO trial shows sustained PFS with Venclexta/Venclyxto + MabThera/Rituxan vs BR in patients with r/r CLL The data showed a reduction in the risk of disease progression or death by 81%, m-OS (82.1% vs 62.2%), patients who completed 2yrs. of treatment without the progressive disease, 63.8% had uMRD The P-III […]Read More
Shots: In terms of the agreement, lilly will commercialize the system, which is currently in development & will include an insulin pump developed & manufactured by ypsomed Ypsomed’s insulin pump has been marketed in europe since 2016, available in 21 countries as the mylife ypsopump. Lilly will commercialize a version of this insulin pump, along […]Read More
Shots: The P-II trial will assess BI 764198 (qd for ~4wks.) in patients hospitalized for COVID-19 with expected enrollment initiation in Oct’2020. The 1EPs will be the percentage of patients who are alive and free of mechanical ventilation at day 29 of treatment while other EPs include clinical improvement, oxygen saturation & ICU admission The […]Read More
Shots: The approval of expanded indication is based on P-III CAPSTONE-2 study assessing Xofluza (40/80mg) vs oseltamivir (75mg bid for 5days) & PBO in people who met CDC criteria for being at high risk of complications from flu aged ≥12yrs. The P-III CAPSTONE-2 study results: reduction in time to improve flu symptoms compared to PBO […]Read More
Shots: The new precision health app, LIFE Extend guides users to adopt five pillars of health which include physical activity, nutrition, mindfulness, sleep and intermittent fasting, enabling the in leading longer & healthier lives LIFE Extend gamifies the five pillars allowing the user to earn LIFE Points by tracking their healthy behaviors with an option […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
